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ABSTRACT
In recent years, tumor Adoptive Cell Therapy (ACT), using administration of ex 
vivo-enhanced T cells from the cancer patient, has become a promising therapeutic 
strategy. However, efficient homing of the anti-tumoral T cells to the tumor or 
metastatic site still remains a substantial hurdle. Yet the tumor site itself attracts both 
tumor-promoting and anti-tumoral immune cell populations through the secretion of 
chemokines. We attempted to identify these chemokines in a model of spontaneous 
metastasis, in order to “hijack” their function by expressing matching chemokine 
receptors on the cytotoxic T cells used in ACT, thus allowing us to enhance the 
recruitment of these therapeutic cells. Here we show that this enabled the modified 
T cells to preferentially home into spontaneous lymph node metastases in the TRAMP 
model, as well as in an inducible tumor model, E.G7-OVA. Due to the improved homing, 
the modified CD8+ T cells displayed an enhanced in vivo protective effect, as seen by a 
significant delay in E.G7-OVA tumor growth. These results offer a proof of principle for 
the tailored application of chemokine receptor modification as a means of improving 
T cell homing to the target tumor, thus enhancing ACT efficacy. Surprisingly, we also 
uncover that the formation of the peri-tumoral fibrotic capsule, which has been shown 
to impede T cell access to tumor, is partially dependent on host T cell presence. This 
finding, which would be impossible to observe in immunodeficient model studies, 
highlights possible conflicting roles that T cells may play in a therapeutic context.
INTRODUCTION
The current standard therapeutic strategy for primary 
cancer patients is surgical ablation and/or chemotherapy. 
For tumors, or -more often- their metastases, that are 
refractive to these treatments, Adoptive Cell Therapy 
(ACT) using administration of cytotoxic CD8+ T cells, 
engineered to improve their specificity for tumor antigens, 
is producing increasingly promising results [1]. Yet, 
even at the experimental level, ACT is far from perfect. 
Extensive research efforts are gradually shedding light 
into different mechanisms of local immunosuppression 
at the tumor site. These mechanisms, which range 
from immunosuppressive regulatory T cells (Treg) and 
Myeloid-Derived Suppressor cells to metabolic changes 
that inhibit cytotoxic T cell activity [2, 3], will have to 
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be overcome in order for the transferred CD8+ T cells 
to efficiently attack the tumor. Indeed, a combination of 
improved identification of tumor antigens and strategies 
designed to combat immunosuppression is yielding 
encouraging results [1]. Yet there still remains a substantial 
hurdle in ensuring that the transferred anti-tumoral T cells 
physically reach and penetrate the tumor or metastatic site. 
This relatively under-studied issue is likely to become a 
bottleneck in any cell-based therapeutic strategy [4].
Cells with pro-tumoral activity are recruited to the 
tumor via the action of chemokines and their receptors. 
In ACT, transferred CD8+ T cells may not necessarily 
express the chemokine receptors required to reach their 
target, or may do so at levels insufficient to respond to 
biochemically-modified chemokines released by the tumor 
site [5]. Within lymphoid structures, T cells have been 
shown to move along a dispersed reticular fiber network, 
thus gaining mobility within the tissue. Conversely, a 
recent pioneering imaging study demonstrated that human 
lung tumors are surrounded by a barrier of dense fibrous 
structures, parallel to the circumference of the tumor 
mass, which inhibit T cell entry [6, 7]. Indeed, a fibrotic 
barrier is thought to restrict access to therapeutic agents in 
lung, pancreatic and breast tumors [2, 8, 9]. Whilst such a 
capsule could initially restrain the tumor, dense collagen 
structures in breast cancer favor tumor progression: the 
extracellular matrix induces activating signals in tumor 
cells, leading to more aggressive and metastasis-prone 
tumors. The spatial organization of the collagen fibers 
gradually changes from dense to parallel barrier-like 
(which can shelter the tumor from immune attack as well 
as promote tumor progression to more aggressive states), 
and to a final more metastasis-prone radial arrangement 
[9]. Thus, at least in some tumors, a fibrotic capsule may 
inhibit immunosurveillance, giving the tumor time to 
become more aggressive. Highly metastatic tumor cell 
lines from various tumors have been shown to correlate 
with enhanced ability to “break through” collagen 
membranes mediated by collagenase enzymes [10], 
suggesting a mechanism for tumor escape in late stages. 
In an experimental mouse spontaneous pancreatic ductal 
adenocarcinoma, genetic depletion of the fibrous stroma 
led to a relative enrichment of infiltrating Treg, resulting 
in tumor growth [2]. In a clinical context of ACT, the 
excluded T cells would be more likely to be transferred 
cytotoxic CD8+ T cells rather than Treg. Salmon and co-
workers indeed have demonstrated that ex vivo collagenase 
treatment enables excluded cytotoxic T cells to penetrate 
the tumor mass. Further, they have shown that the intact 
fibrotic barrier can be overcome by cytotoxic T cells when 
the xenotransplanted human tumor used as a target was 
made to overexpress the chemokine CCL5 [6]. These 
seminal findings have brought insight into the processes 
inhibiting efficient migration of anti-tumor T cells to 
the target site in ACT; yet they do not directly translate 
to therapy proposals. For this reason, clinically-relevant 
proof-of-principle solutions are still needed. 
A strategy that has potential for translation to the 
clinic involves ectopically expressing a chemokine 
receptor on the T cells that can force their recruitment to 
the target site. As T cells are virally transduced in most 
ACT protocols in order to modify their specificity towards 
tumor-associated antigens [1], addition of a chemokine 
receptor-expressing vector can be achieved with 
minimal modifications to ACT protocols. In this context, 
chemokine receptors have been shown, by us and others, 
to be able to re-direct T cell migration in physiological in 
vivo conditions [11], in vitro towards chemokines detected 
in tumors [12], as well as in vivo towards implanted 
tumors [13-15]. To further the translational relevance 
of this strategy, it would be important, as a proof of 
principle, to tailor the approach to spontaneous tumors. 
For this, here we utilized the transgenic adenocarcinoma 
of mouse prostate (TRAMP), a mouse model of prostate 
cancer, one of the tumors with highest associated mortality 
[16]. Male TRAMP mice closely mirror the pathology of 
human prostate cancer and, importantly, spontaneously 
form lymph node and lung metastases [17]. We analyzed 
the chemokine expression pattern of the lymph node 
metastases in TRAMP mice. We identified the chemokine 
most robustly expressed in the spontaneous metastatic 
lymph nodes, cloned a vector encoding its matching 
chemokine receptor and utilized it to transduce CD8+ T 
cells, along with constructs encoding for tumor-specific 
T cell receptors. This enabled the modified T cells to 
preferentially home into metastatic lymph nodes, as 
demonstrated by flow cytometry and 2-photon microscopy. 
We show that the modified CD8+ T cells maintain intact 
their in vitro killing capacity, whilst, due to the improved 
homing, they display an improvement in in vivo anti-
tumor activity, as seen by a delay in tumor growth. Thus 
chemokine receptor-modified T cells can enable CD8+ 
T cells in ACT to gain enhanced access to the tumor. 
Surprisingly, by examining the levels of tumor-associated 
fibrosis in mice lacking T cells, we uncover that the peri-
tumoral fibrotic capsule, which can impede T cell access 
[6] and is thus part of the obstacles to therapy, is partially 
dependent on host T cell presence for its formation. 
This finding, which would not be possible to observe in 
immunodeficient xenotransplantation models, highlights 
the intriguing possibility that T cells in a therapeutic 
context may play conflicting roles.
RESULTS
CCL2 expression is robustly upregulated in sites 
of spontaneous lymph node metastasis in TRAMP
Tumors secrete a number of different chemokines, 
which can mediate both the metastasis of the tumor itself 
Oncotarget43012www.impactjournals.com/oncotarget
as well as the recruitment and/or retention of cells with 
pro- or anti-tumoral function [18]. We hypothesized 
that by identifying the existing chemokine gradients in 
a spontaneous tumor metastasis, we would be able to 
“hijack” the gradient in order to enhance the migration of 
adoptively transferred anti-tumoral CD8+ cytotoxic T cells. 
The primary tumor in prostate cancer is usually surgically 
removed, thus rendering more clinically relevant an 
ACT treatment for metastasis rather than primary tumor. 
TRAMP mice spontaneously form lymph node and lung 
metastases [17]. We performed pilot experiments to 
identify the timing with which the spontaneous lymph 
node metastases in TRAMP occur, as the literature is 
equivocal on this point. We identified that at 26 weeks 
of age a high (but variable) percentage of TRAMP male 
mice developed metastasis in the inguinal and para-aortic 
lymph nodes. To identify the presence of metastasis, we 
analyzed all explanted lymph nodes by real-time qPCR 
and immunohistochemistry (IHC) (Supplemental Figure 
1) for the expression of the SV40 large T antigen (SV40 
TAg), which is part of the transgene driving oncogenesis 
[17]. SV40 TAg expression guarantees tumor presence, 
though its absence may indicate either lack of tumor or 
tumor that has lost expression of the antigen. Thus in all 
our assays we only considered SV40 TAg+ lymph nodes 
as metastatic and used age-matched healthy C57BL/6 
lymph nodes rather than TRAMP SV40 TAg- lymph 
nodes as healthy controls. Human and murine prostate 
tumors have been previously reported to express CCL2, 
CCL5 and CXCL12 [18-24]. We thus examined, by 
real-time qPCR, the expression of these chemokines in 
metastatic lymph nodes. We also assessed the expression 
of other chemokines, such CXCR3 ligands, that have been 
associated with inflammation and primary cancers [25]. 
CCL2 mRNA displayed extremely statistically significant 
upregulation in metastatic versus healthy lymph nodes 
(P<0.001, Mann Whitney test) (Figure 1A). CXCR3 
ligands also displayed potentially exploitable differences 
in expression, especially CXCL10 (Figure 1D-F). Results 
for the primary tumor mass in the prostate reflected the 
same trend, albeit with lower statistical significance 
(Supplemental Figure 2A). On the basis of these results, 
either CCR2 or CXCR3, as cognate receptors for CCL2 
and CXCL10 respectively, could be equally used in 
chemokine receptor-modified ACT. Given the extensive 
reports on CCL2 expression in prostate cancer [22, 24, 
26], we chose to utilize CCR2.
Figure 1: Ccl2 mRNA is differentially upregulated in TRAMP metastatic lymph nodes. A: Ccl2 mRNA relative expression 
in TRAMP SV40+ or healthy lymph nodes; Mann Whitney test: (***) P<0.001. B: Ccl5 mRNA relative expression in TRAMP SV40+ or 
healthy lymph nodes; Mann Whitney test: (ns) P>0.05. C: Cxcl12 mRNA relative expression in TRAMP SV40+ or healthy lymph nodes; 
Mann Whitney test: (*) P< 0.05. D: Cxcl9 mRNA relative expression in TRAMP SV40+ or healthy lymph nodes; Mann Whitney test: (**) 
P< 0.01. E: Cxcl10 mRNA relative expression in TRAMP SV40+ or healthy lymph nodes; Mann Whitney test: (***) P< 0.001. F: Cxcl11 
mRNA relative expression in TRAMP SV40+ or healthy lymph nodes; Mann Whitney test: (**) P< 0.01.
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ACT with concurrent transduction of the 
chemokine receptor for CCL2 boosts homing of 
CD8+ T cells to the site of spontaneous metastasis 
in TRAMP
We thus next set out to perform ACT using CD8+ 
T cells from healthy C57BL/6 donors transduced with 
a T cell receptor construct conferring specificity for 
the antigen SV40 TAg, which is expressed in TRAMP 
[27]. Concurrently, we co-transduced a retroviral vector 
expressing CCR2 or a GFP control vector. The CCR2-
expressing vector was capable of enhancing in vitro 
migration towards CCL2 (Supplemental Figure 2B) 
compared to control-transduced cells; this is unsurprising, 
as CCR2 is known to be expressed at very low levels in 
T cells [5]. 
The transduced cells were thus administered to 
26 week-old TRAMP male ACT recipients. To examine 
whether CCR2 transduction improved T cell homing 
to TRAMP metastatic lymph nodes, we assessed by 
flow cytometry the presence of GFP+ cells in single cell 
suspensions of recipient lymph nodes harvested 24 hours 
after T cell transfer. Cells from each analyzed lymph 
node were examined in parallel by qPCR for SV40 TAg 
expression, as above, to confirm that they were indeed 
metastatic. The concurrent transduction with CCR2 
significantly improved homing to metastatic lymph nodes 
Figure 2: CCR2 transduction significantly improves homing to the metastatic lymph nodes. A: percentage of GFP-CCR2 
(n=13) or GFP-control (n=9) injected cells recovered from TRAMP SV40 TAg+ lymph nodes, 24 hours after adoptive transfer, analyzed by 
FACS; Mann Whitney test: (*) P<0.05. B: percentage of GFP-CCR2 (n=9) or GFP-control (n=10) injected cells, recovered from TRAMP 
spleens, 24 hours after adoptive transfer, analyzed by FACS; Mann Whitney test: (ns) P>0.05. C: density of GFP-CCR2 (n=4) versus GFP-
control (n=6) in TRAMP SV40 TAg+ lymph nodes (cells per mm3), 24 hours after adoptive transfer, analyzed by 2-photon microscopy; 
unpaired t test: (*) P<0.05 (top). D: Representative images of SV40 TAg+ lymph nodes acquired by 2-photon microscopy. Lymph node from 
a recipient of GFP-control CD8+ T cells on the left; from a recipient of GFP-CCR2 CD8+ T cells on the right. Green signal indicates GFP+ 
cells; collagen stain by SHG shown in white. 
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(P<0.05, Mann Whitney test) (Figure 2A), whilst this was 
not so in off-target tissues such as the spleen (Figure 2B). A 
number of recipient lymph nodes were analyzed ex vivo by 
2-photon microscopy, enabling the visualization of GFP+ 
cells. Comparison of the number of GFP+ cells in CCR2-
transduced versus control-transduced T cell recipients 
confirmed that indeed CCR2 transduction significantly 
improves homing to the SV40 TAg+ metastatic lymph 
nodes (P<0.05, unpaired t test) (Figure 2C, D). Double 
staining of lymph node sections for tumor cells and T cells 
(using anti-SV40 TAg and anti-GFP antibodies) identified 
that the CCR2-transduced T cells were in contact with 
tumor cells (Supplemental Figure 3).
Chemokine receptor transduction of CD8+ T cells 
does not affect their cytotoxic potential or state of 
activation
In order to assess whether the improvement in 
homing is reflected in in vivo anti-tumor activity, we 
decided to monitor tumor growth in vivo during ACT with 
CCR2- or control-transduced CD8+ T cells. The metastasis 
in the lymph nodes of TRAMP mice does not form well-
defined solid structures, which would be necessary to 
enable quantification of tumor size in vivo. For this reason, 
we opted to utilize an injectable tumor cell line. Whilst 
TRAMP-derived cell lines do exist, they have lost the 
expression of the SV40 large T antigen, thus rendering a 
“standard” ACT using T cells transduced with a tumor-
specific TCR impossible. We thus chose to inject C57BL/6 
mice with the tumor cell line E.G7-OVA, a lymphoma 
cell line expressing the antigen ovalbumin as well as 
similar levels of CCL2 compared with TRAMP metastatic 
lymph nodes (Supplemental Figure 4). To rule out any 
possible negative functional side-effects of chemokine 
receptor transduction on the CD8+ T cells, we performed 
in vitro T cell-mediated cytotoxicity assays, using E.G7-
OVA cells as targets (Figure 3A). The CD8+ T cells were 
transduced with a TCR specific for ovalbumin [28] as well 
as constructs for CCR2 or a control vector. The results 
confirmed that CCR2 transduction does not negatively 
affect CD8+ T cell cytotoxic function. 
A number of chemokines have been shown to be 
able to provide costimulation signals to T cells, leading to 
enhanced T cell activation [29]. This has also been shown 
to occur with CCL2 [30, 31]. Thus we could not exclude 
the possibility that transduction of CCR2 in CD8+ T cells 
could enable them to receive costimulatory signals from 
CCL2, in addition to improving their homing towards 
CCL2. To test this, we set up in vitro costimulation 
assays, using T cells that had been transduced with CCR2 
or control vectors. The assays were performed 48h after 
transduction, so as to match the timing of injection for 
ACT. We found that CCL2 did not have any costimulatory 
effect on the T cells, as judged by expression of activation 
markers CD69 and CD25 (Figure 3B, 3C). However, 
this does not preclude that CCL2 per se cannot mediate 
costimulation. Rather, it is likely that the activation and 
costimulation received by the T cells in order to transduce 
them in the first place (see Materials and Methods), renders 
any further costimulation unnecessary or impossible, as 
indeed is the case for pre-activated T cells [32]. Indeed, in 
our assays, costimulation of the transduced cells was not 
Figure 3: Chemokine receptor transduction does not affect killing capacity or activation state of CD8+ T cells. A: Lack 
of effect of chemokine receptor transduction in in vitro T cell-mediated cytotoxicity. Target (5x104 E.G7-OVA) cells were co-incubated 
with increasing concentrations of OVA-specific TCR/GFP-control or OVA-specific TCR/GFP-CCR2 transduced CD8+ T cells as effector 
cells. The target cells were labeled with Orange CMTMR Dye and cell death was assessed by 7-AAD. The percentage of dead target cells 
was evaluated by flow cytometry; 2-way repeated measures ANOVA: (ns) (P>0.05). B: Lack of costimulatory effects of chemokine ligand 
on chemokine receptor-transduced CD8+ T cells. CCL2 costimulation assays were performed with GFP-CCR2 or GFP-control-transduced 
CD8+ T cells. Activation markers CD25 and CD69 were measured by flow cytometry 18h after stimulation. 2-way ANOVA: (***) P<0.001; 
(ns) P>0.05.
Oncotarget43015www.impactjournals.com/oncotarget
evident even with the administration of “classical” anti-
CD28 costimulatory signals (Figure 3B, 3C). Thus it is 
unlikely that CCL2 may be costimulating the transferred 
T cells in our experimental ACT setup.
CD8+ cells transduced for CCR2 infiltrate the 
tumor mass and significantly delay tumor growth 
in vivo
We next proceeded to perform ACT on mice that 
had received E.G7-OVA tumors subcutaneously. In 
order to remain as close as possible to clinically-relevant 
limitations, we utilized a mild ACT regimen, with no 
concurrent administration of adjuvants, using T cells 
transduced with CCR2 or control vectors as well as a 
vector expressing ovalbumin-specific TCR. The latter 
choice, despite its lower efficiency in rendering tumor 
antigen-specificity compared to transgenic antigen-specific 
T cells, was preferred due to its vicinity to clinically 
applicable solutions. Mice were divided into three groups, 
each group receiving CCR2- or control-transduced 
CD8+ T cells or no ACT. A first T cell administration 
was performed 8 days after tumor injection, as shown 
in the schematic outline (Figure 4, schematic diagram). 
Tumors were monitored by in vivo fluorescence detection 
of an integrin marker. 8 days after the first ACT (Figure 
4 – day 16), we observed a significant reduction (close 
to 50%) in tumor mass in the group treated with T cells 
transduced with OVA-specific TCR/CCR2 compared to 
tumors in mice that received no ACT or mice that received 
T cells transduced only with the TCR and GFP-control 
vectors. Thus the chemokine receptor-modified CD8+ T 
cells exhibited an improved control over tumor growth. 
Administration of further T cells with a second ACT 
eliminated the difference between CCR2- and control-
transduced T cells by day 24, though CCR2-transduced T 
cells still resulted in a significant –albeit poor- restraining 
of tumor growth (Figure 4 – day 24). We speculate that 
the aggressive tumor growth by day 24, which is not 
unexpected given the “weak” ACT regimen followed, 
may account for the loss of significant difference between 
the two treatments. Nonetheless, these results demonstrate 
that tailored modification of the chemokine receptor in 
CD8+ T cells used in ACT can have a significant effect in 
slowing down tumor growth.
As CCR2-transduced CD8+ T cells do not differ in 
in vitro cytotoxic capacity from control-transduced cells, 
any beneficial effect on tumor growth was likely to be 
due to improved homing. Indeed, when we evaluated by 
immunohistochemistry the presence of GFP+ cells in the 
implanted E.G7-OVA tumors, we observed a significantly 
greater number of cells in the recipients of CCR2-
transduced compared to control-transduced CD8+ T cells 
(Figure 5A, B). This result confirms, in a different tumor 
model, that tailored chemokine receptor modification 
improves T cell homing, matching our findings in TRAMP 
spontaneous metastatic lymph nodes.
TRAMP metastatic sites are characterized by 
increased fibrosis
The pro-tumoral barrier function of the fibrous 
formations of collagen is usually associated with 
pancreatic, lung and breast tumors [2, 8, 9]. The 
metastatic lymph nodes in the TRAMP model would 
clearly not pose any such barrier to T cell entry, as the 
lymph node is physiologically accessible to lymphocytes. 
Nonetheless, we enquired whether the increased collagen 
deposition associated with the fibrosis-prone tumors 
could also be observed in these spontaneous prostate 
cancer metastases. Utilizing second harmonic generation 
in 2-photon microscopy, which enables visualization of 
collagen in situ, we examined collagen deposition in SV40 
TAg+ metastatic or healthy lymph nodes. The metastatic 
lymph nodes had significantly higher levels of collagen 
(Supplemental Figure 5), suggesting that cancer-associated 
fibrosis could be associated with tumors not considered 
“fibrosis-prone”. 
The presence of T cells reduces tumor size but 
favors peri-tumoral fibrosis formation
A putatively more ubiquitous presence of fibrosis 
associated with tumors led us to form a hypothesis as to 
why such structures may form within diffuse tumors or 
around solid tumors. Tumors are thought to behave as 
never-healing wounds [33]. Intriguingly, T cells have been 
suggested to play an important role in fibrosis formation 
during wound healing [34], whilst Th2-polarized cells 
correlate with tumor-promoting inflammation [35]. We 
thus hypothesized that (host) T cells could be contributing 
to the formation of tumor-associated fibrosis. To test 
this, we injected cells from a pancreatic tumor cell line, 
PANC02, into T and B cell-deficient RAG2-/- mice or 
wild-type C57BL/6 controls. After 3 weeks of tumor 
growth, we examined the size of the explanted tumors 
as well as the formation of a fibrotic capsule around the 
solid tumors. Unsurprisingly, given the well-characterized 
role of T cells in immunosurveillance [36], RAG2-/- 
recipients developed significantly larger tumors than the 
wild-type recipients (Figure 6A). Surprisingly, however, 
the tumors in RAG2-/- mice had significantly less dense 
peri-tumoral collagen than wild-type mouse tumors, as 
assessed by Masson’s trichrome staining (Figure 6B, 6C), 
as well as by second harmonic generation in 2-photon 
microscopy (Supplemental Figure 6). This suggests that 
T cell presence contributes to the formation of the tumor-
associated fibrotic capsule.
As mentioned above, the peri-tumoral fibrotic 
capsule has been shown to inhibit T cell infiltration into 
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Figure 4: Chemokine receptor-modified CD8+ T cells lead to significant delay in tumor growth. Top: experimental design 
scheme. Images and plots: (DAY 16) in vivo Integrisense radiance emission detection of implanted E.G7-OVA tumor, 8 days after the 
first adoptive transfer of CCR2 (n=8) or GFP-control (n=8) transduced cells or no transfer (n=9); 1-way ANOVA and Tukey’s multiple 
comparison test: (*) P<0.05. (DAY 24) Integrisense radiance emission of harvested E.G7-OVA tumor, 8 days after the second adoptive 
transfer of CCR2 (n=8) or GFP-control (n=7) transduced cells or no transfer (n=9); 1-way ANOVA and Tukey’s multiple comparison test: 
(*) P<0.05. Data are displayed as mean + SEM of radiance for each group of animals at a given time point. 
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tumors [2, 6]. We thus asked whether the reduction in 
collagen density that we observed in 3-week tumors from 
T cell-deficient RAG2-/- mice would lead to greater ease of 
infiltration by T cells. To assess this, we had to compare 
T cell infiltration in tumors grown in the presence or in 
the absence of T cells. We thus first analyzed sections 
of tumors extracted after 3 weeks of growth in control T 
cell-sufficient C57BL/6 tumor recipients. We examined 
the distribution of T cells across the tumor, identifying 
the presence T cells via immunohistochemistry for CD3 
(Figure 6D, upper line and Supplemental Figure 7). On 
the other hand, in the absence of T cells (i.e. in RAG2-/- 
tumor recipients), the host has no T cells that may infiltrate 
the tumor. Thus to examine T cell infiltration in tumors 
grown in the absence of T cells, we transferred 3x106 CD3+ 
T cells into a cohort of PANC02 tumor-bearing RAG2-/- 
mice, 3 days before harvesting their 3-week-old PANC02 
tumors. To facilitate the identification of the transferred T 
cells, we stained them with Cell Tracker Orange CMTMR 
dye prior to injection. Using 2-photon microscopy on the 
extracted tumor sections, we identified transferred T cells 
via their fluorescence and peri-tumoral capsules via second 
harmonic generation (Supplemental Figure 7). Staining 
with CMTMR introduces an uncontrolled variable, 
which could affect the total number of T cells measured. 
Yet, we were interested in how T cells were distributed 
across the tumor (the gradient of the distribution of T 
cells), a parameter that is both independent of the absolute 
number of total T cells present (within a physiological 
range of cell concentrations) as well as independent 
of the method of detection of the T cells in each group. 
Indeed, the total number of transferred T cells present 
in the RAG2-/- recipients would be expected to be lower 
than the total number of T cells present in control T cell-
sufficient hosts. Reflecting this, the total number of T cells 
detected in RAG2-/- recipient tumors was lower than in 
C57BL/6 tumors (Figure 6D, upper versus lower lines). 
Yet, when we applied an image analysis algorithm on 
both groups (see Methods) to assess the way in which T 
cell density distribution changed along concentric regions 
starting from the outer tumor border and moving towards 
the center of the tumor, C57BL/6 tumors produced a 
cell density distribution that fit an exponential decay 
regression model (Figure 6D, upper line). This shows that 
a decreasing number of T cells are found deeper within 
the tumor, suggesting that the tumor capsule in C57BL/6 
(the region marked “tumor capsule”, corresponding to the 
outermost 250 µm of the tumors in Figure 6D) impedes 
the infiltration of T cells. On the other hand, T cell density 
distribution across the tumor in RAG2-/- mice fit a linear 
model, with a slope that did not significantly differ from 
a flat line (P>0.05, linear regression) (Figure 6D, lower 
line). This flat distribution suggests that in tumors grown 
in T cell-less recipients, possibly due to the lower density 
collagen of the tumor capsule, introduced T cells can 
move into the tumor without the impediment observed 
in control tumors. Finally, in order to compare the two 
rates of decay, we performed a logarithmic transform of 
the distribution data and applied a linear regression model, 
restricted to the region of the tumor capsule (Figure 6E). 
The two slopes were significantly different (P<0.05, linear 
regression). This signifies that the “flat” distribution of 
infiltrating T cells in RAG2-/- tumors differs significantly 
from that of control mice. Thus T cell infiltration across 
tumor capsules in T cell-sufficient mice appears to be 
inhibited in a manner that is absent from T cell-deficient 
mice. Thus, taken together, the above suggest that (host) T 
cells contribute to capsule formation, which may obstruct 
T cell infiltration of the tumor.
The RAG2-/- mice that we utilized for the above 
analysis are deficient in both T and B cells. We thus sought 
to further dissect whether the effects on the peritumoral 
fibrotic capsule could be attributed to only one of these 
lymphocyte populations. To achieve this, we depleted the 
B cells from a cohort of C57BL/6 mice by administering a 
mouse anti-mouse CD20 antibody, using vehicle (saline) 
Figure 5: Enhancement in ACT efficacy is associated with improved homing of chemokine receptor-modified CD8+ T 
cells. A: Density of injected cells in E.G7-OVA implanted tumors (cells per µm2), at the end of therapy; Mann Whitney test, recipients of 
GFP-CCR2 (n=8) versus GFP-control (n=7) transduced T cells: (**) P<0.01 B: Representative images of immunohistochemical analysis: 
Brown staining/red arrows: GFP+ cells (GFP-ctrl+ or GFP-CCR2+ CD8+ T cells).
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Figure 6: Host T cell presence inhibits tumor growth but simultaneously favors fibrosis formation. A: PANC02 tumor 
size, shown as tumor area after 3 weeks of in vivo growth, in the presence (C57BL/6J recipients) or absence (RAG2-/- recipients) of host 
T cells; Mann Whitney test: (*) P<0.05. Each dot represents one animal. B: Representative images of Masson’s trichrome staining of 
harvested PANC02 tumor sections. Collagen stain visible in green/cyan color. Boxes show the areas from which regions of interest were 
obtained to calculate mean collagen density for every sample. Scale bars represent 50 µm. C: collagen density in the presence (C57BL/6J 
recipients) or absence (RAG2-/- recipients) of host T cells; Mann Whitney test (**) P<0.01. Each dot represents one animal. D: T cell density 
distribution across PANC02 tumors grown for 3 weeks in C57BL/6 recipients that are T cell-sufficient (n=5) or in RAG2-/- recipients in 
which CD3+ cells were injected 3 days prior to analysis (n=8). Y-axis values represent the mean T cell density ± SEM in concentric regions 
starting from the outer tumor capsule border and moving towards the center of the tumor (examples of the regions shown in Supplemental 
Figure 7). X-axis values show the distance of the region from the outer tumor capsule border. The vertical dotted line marks the estimated 
average inner edge of the tumor capsule, derived from 2PM SHG imaging. 95% confidence intervals are also shown. The slope of the 
RAG2-/- recipients is not different from a flat line (P>0.05, linear regression). E: Natural logarithmic transform of the T cell distributions, for 
the region covering the average capsule width (0-250 µm from the outer tumor border). Data points shown as mean ± SEM; 95% confidence 
intervals are also shown. The two slopes are significantly different (*: P<0.05, linear regression).
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treatment as control. In parallel, we treated another 
cohort of C57BL/6 with an armenian hamster anti-mouse 
CD3e antibody (or isotype control), in order to deplete T 
cells. Four days later, all mice received subcutaneously 
PANC02 tumor cells, whilst their T and B cell levels 
were regularly monitored (Figure 7). 3 weeks after tumor 
injection, we sacrificed all recipients and analyzed the 
formation of peri-tumoral capsules (Figure 7A,7B). B cell 
depletion appeared to slightly reduce capsule formation, 
yet no significant effect was observed (Figure 7B, left 
segment). On the other hand, T cell depletion did lead 
to a significant reduction in collagen deposition in the 
peritumoral capsule (Figure 7B, right segment). This 
finding lends further support to our interpretation above, 
that T cells significantly contribute to the formation of a 
peritumoral fibrotic capsule. Nonetheless, it would not 
be prudent to exclude that B cells could also contribute 
to capsule formation; yet the weak effect observed will 
require far more extensive studies in order to provide a 
more definitive answer.
DISCUSSION
Efficient adoptive cell therapy to combat established 
tumors depends upon a sufficient number of cytotoxic 
T cells, with high avidity for tumor antigen, reaching 
the tumor site without being dispersed in healthy tissue 
[14, 37]. The results presented here demonstrate that 
a substantial benefit can be obtained by ectopically 
expressing on the transferred T cells a chemokine receptor 
cognate for a chemokine that is strongly and differentially 
produced at the tumor site. Our approach significantly 
improves directed homing to the tumor, as demonstrated 
in two different experimental systems: in spontaneous 
lymph node metastases of prostate adenocarcinoma mice 
as well as in implanted E.G7-OVA lymphoma. As a result, 
a significant delay in tumor growth was obtained. Our 
proof-of-principle approach is novel in being applied to 
a spontaneous tumor model. By tailoring the receptor 
modification to match any chemokine identified in the 
metastasis, whichever this may be, the strategy could 
theoretically be applied to any unknown tumor. Indeed, it 
would be exceptionally suited to the treatment of diffuse 
metastasis, where a biopsy of a single accessible metastatic 
site could be used to identify the chemokine secretion 
signature of less accessible sites. This is highly relevant 
to prostate cancer, where diffuse metastatic relapse 
often occurs after the primary tumor has been surgically 
removed [38]. Unlike experimental ACT, which can be 
easily enhanced by the combination of several auxiliary 
boosting protocols, in the clinic ACT is often sub-optimal 
[1]. In such conditions, incremental improvements that can 
be added with minor protocol modifications, such as the 
addition of a second viral construct during the transduction 
of the specificity-conferring TCR, could be essential in 
enhancing the overall efficacy of the therapy.
We also found that the presence of prostate 
cancer metastasis in a lymph node was associated with 
increased collagen deposition. Whilst such a correlation 
is well-described in “fibrosis-prone” tumors [2, 8, 9], our 
finding led us to speculate that tumor fibrosis might be a 
phenomenon inherently linked to tumor presence per se 
rather than to specific “fibrosis-prone” tissues. Fibrosis is a 
physiological response that occurs during wound healing; 
intriguingly, the formation of tumor stroma is thought to 
share many characteristics with healing wounds, albeit 
with a chronic, non-resolving nature [33]. Fibrosis in 
the context of wound-healing is linked to persistent 
type-2 immunity [39] and appears to be dependent on 
T cell presence [34]. Type-2 (“alternative”) immunity 
during infections requires the presence of Th2 cells to 
maintain its chronicity [40]. In the liver, Th2 cells assist 
fibroblasts in promoting fibrosis [41]. In the context of 
tumors, where fibroblasts may be tumor-promoting FAP+ 
Cancer-Associated Fibroblasts [42], Th2 cells contribute 
to pro-tumoral inflammation in pancreatic [35] and 
breast cancers [43]. Whilst there is ample evidence that 
the collagen deposition per se is likely to be mediated by 
the combined action of tumor-infiltrating macrophages 
and cancer-associated fibroblasts [2, 44-47], the reports 
discussed above, taken together, hint that T cells (with 
a Th2 polarization) may play a role in the formation of 
pro-tumoral fibrosis. One can speculate that this may be 
occurring via their effect on the chronicity of the pro-
fibrotic innate inflammatory response [40].
The experiments we present here give further 
support to the above conclusions, by showing that, in an 
ectopically injected pancreatic (thus fibrosis-prone) tumor 
model, T cell deficiency significantly reduces the extent of 
fibrosis and the ability of T cells to infiltrate the tumor. Our 
functional demonstration of impaired T cell infiltration in 
T cell-sufficient recipients contains the important caveat 
that we did not use externally administered labeled T cells 
in T cell-sufficient recipients as an additional control. Yet, 
as the only parameter measured was the gradient of the 
infiltrating cell distribution, which reflects the accessibility 
of the tumor, it is unlikely that this would result in a 
different distribution gradient, as indeed already existing 
T cells were impeded in their infiltration. Similarly, as 
the RAG2-/- mice we utilized are T and B cell-deficient, 
we cannot formally exclude that B cells have a role in 
promoting peritumoral fibrosis. This would be consistent 
with their ability to induce production of pro-fibrotic 
cytokines [48, 49]. Nonetheless, in our antibody-mediated 
depletion experiments, removal of T cells had a stronger 
and significant effect, compared to removal of B cells. 
Thus fibrosis is, at least partially, dependent on T cell 
presence. To our knowledge, the T cell-dependent fibrosis 
formation that we observed has never been reported 
before. Partly, this could be attributed to the fact that 
many clinically-relevant ACT studies are performed in 
xenotransplantation-permissive immunodeficient models, 
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which have no host T cells. Further, the duration of the 
treatment may be too short to allow development of pro-
fibrotic Th2 cells.
Ever since the demonstration of T cell-mediated 
immunosurveillance [36], pro-inflammatory T cells have 
been considered an essential weapon in the battle against 
tumors. Indeed the central principle underlying ACT is 
their ability to attack the tumor mass or metastasis. For 
this, it is envisaged that they should be administered to 
patients in as “stem cell-like” a state as possible [1, 50], to 
guarantee their long-lasting in vivo functionality. As CD4+ 
T helper cells have been shown to significantly contribute 
to boosting anti-tumor cytoxicity [51], a co-transfer of 
CD4+ and CD8+ T cells can be envisaged as being part 
of optimized ACT protocols. Yet our results enable the 
speculation that a proportion of long-surviving CD4+ T 
cells transferred into a cancer patient could, theoretically 
and eventually, become polarized to a Th2 phenotype. 
These cells would thus assist in the formation of tumor-
promoting fibrotic capsules, protecting any surviving 
tumor/metastatic foci, the very same targets that ACT is 
designed to combat. 
The potential conflicting function of immune cells 
in their interaction with cancer is not a new concept, 
especially in innate immunity [52]. Yet T cell-mediated 
therapy studies occasionally neglect that pro-inflammatory 
T cells can be pro-tumoral [35, 43]. Our data demonstrates 
that tailored chemokine receptor modification can be used 
to enhance the homing efficacy of the transferred T cells 
in ACT. Yet our data also offers a hint that T cells present 
in the same organism are partly responsible for the fibrotic 
structures that may, in some cases, be protecting tumors 
from T cell attack. It could, therefore, be sensible to apply 
anti-fibrotic or anti-type 2 therapies [53] in combination 
with T cell-mediated ACT, so as to avoid that (some of) 
the cells that are being used therapeutically could end up 
contributing to the disease.
MATERIALS AND METHODS
Mice and tumor cell lines
TRAMP and C57BL/6J mice were sourced from 
Charles River Laboratories. Heterozygous TRAMP 
used in the experiments were obtained and screened as 
in [17]. Mice were treated in accordance with European 
legislation and local regulations. E.G7-OVA (ATCC 
CRL-2113) cells derived from murine lymphoma EL4 
that express OVA constitutively (kindly provided by Dr. 
R. Bonecchi, Humanitas Clinical and Research Center, 
Italy) were cultured in RPMI 1640 medium with 2 
mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L 
glucose, 10 mM HEPES, 1.0 mM sodium pyruvate, 
0.05 mM 2-mercaptoethanol, 0.4 mg/ml G418 and 10% 
fetal bovine serum. HEK-293 cells derived from human 
embryonic kidney cells were cultured in the presence 
of high-glucose medium Iscove’s Modified Dulbecco’s 
Medium (IMDM) with L-glutamine, in the presence 
of 0.001% 2-mercaptoethanol, 25 U/ml penicillin and 
streptomycin and 10% fetal calf serum. PANC02 cells 
derived from murine pancreas ductal adenocarcinoma 
[54] were cultured in RPMI 1640 medium with 2 mM 
L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 
10 mM HEPES, 1.0 mM sodium pyruvate, 0.05 mM 
2-mercaptoethanol and 10% fetal bovine serum.
CD8+ T isolation and activation
CD8+ T cells were isolated from spleens and 
inguinal lymph nodes of C57BL/6 mice using CD8a+ 
T cell Isolation Kit II (Miltenyi Biotec). The purity 
obtained was assessed by staining for anti-mouse CD8-
PE (eBioscience) and analyzing on FACS (BD) and 
was always higher than 90%. CD8+ T cells were plated 
overnight at 1.5 x 106 cells/well in IMDM containing 10 
ng/ml rmIL-2, 10 ng /ml rmIL-7, 10 ng/ml rhIL-15 (all 
PeproTech) in 24 well plates previously coated with 2 µg/
ml NA/LE anti-mouse CD3ε (BD) and 1 µg/ml NA/LE 
anti-mouse CD28 (BD Pharmingen).
Retroviral transduction of T cells 
The day before transfection, 2.4x106 HEK-293 
cells were plated onto 6 well plates (BD) using 12 ml 
of Iscove’s Modified Dulbecco’s Medium (IMDM) high 
glucose with L-glutamine, 0.001% 2-mercaptoethanol and 
10% fetal calf serum. Transfection of retroviral constructs 
was performed in Optimem (Gibco) with Lipofectamine 
2000 at 1.6% (Invitrogen), using 2 µg of packaging vector 
pCL-Eco (Imgenex) and combination of the following 
plasmids: i) m6p-egfp[Blast] [11] Green Fluorescent 
Protein (EGFP) control, (kind gift of Dr Randow and Dr 
Betz, MRC-LMB, Cambridge, UK) ii) m5p-CCR2-2A-
egfp, created by inserting a T2A self-cleaving sequence 
in between a mouse CCR2 (cloned from cDNA) and 
EGFP [55] iii) pMX-SV40α-IRES-SV40β, encoding a 
TCR specific for SV40 Large T antigen [27] (kind gift 
of Dr Schumancher NKI, Amsterdam, NL) and iv) TCR 
OTI-2A.pMIG II, encoding a TCR specific for ovalbumin 
[56] (Addgene). 48 hours post-transfection, filtered viral 
supernatants supplemented with fresh IL-2/IL-7/IL-
15 were added to T cells (at 1.5 x 106 cells/ml) that had 
been purified and activated the previous day. The cellular 
suspension was seeded into Retronectin (Takara Bio) 
coated plate (2ml/well), spun at 1200g for 1h at 30°C 
and incubated overnight at 37°C/5% CO2. The following 
day T cells were collected, washed and allowed to rest 
in medium containing 10% FCS and IL-2/IL-7/IL-15 in 
24 well plates for 48 hours at 37°C/5% CO2. HEK-293 
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transfection and CD8+ T cell transduction efficiency were 
assessed on FACS by examining EGFP expression as well 
as by staining for the T cell receptor (TCR) constructs used 
for ACT: for the SV40 Large T antigen-specific TCR, anti-
Vbeta9 TCR (eBioscience) was used; for the Ovalbumin-
specific TCR coexpression of anti-Valpha2 TCR and anti-
Vbeta 5.1/5.2 TCR (eBioscience) was assessed. The cells 
were then used for in vitro or in vivo assays. 
Immunohistochemistry for SV40 TAg detection
Sample sections on slides were deparaffinized 
and hydrated through a descending scale of alcohols. 
Antigen retrieval was performed using DIVA (Biocare 
Medical). Sections were cooled, washed with PBS 
(Lonza) containing 0.05% Tween 20 (Sigma). Endogenous 
peroxidase was blocked by incubation with Peroxidase I 
(Biocare Medical) for 20 min at room temperature (RT) 
and nonspecific sites were blocked with Rodent Block 
(Biocare Medical) 20 min at RT. The sections were 
incubated for 1h at RT with rabbit anti SV-40 (Santa 
Cruz Biotech V-300) diluted 1:250, washed, incubated 
for 30 min at RT with anti-rabbit HRP polymer (Biocare 
Medical). Sections were incubated with DAB (Biocare 
Medical), counterstained with hematoxylin, dehydrated 
through an ascending scale of alcohols and xylene, and 
mounted with coverslips using Eukitt (Fluka). 
Analysis of in vivo homing 
Recipient TRAMP mice received cells i.v. that were 
either transduced with i) pMX-SV40α-IRES-SV40β and 
m6p-egfp[Blast] or ii) with pMX-SV40α-IRES-SV40β 
and m5p-CCR2-2A-egfp. The same number of EGFP+ 
cells (control or CCR2-expressing) were injected in all 
recipients (5x105 to 106, varying between but not within 
experiments). After 24 hours, inguinal and para-aortic 
lymph nodes and spleen were harvested to assess homing 
of the transferred EGFP+ cells within these tissues. Single 
cell suspensions of spleens were obtained using 70µm 
cell strainers. Inguinal and para-aortic lymph nodes 
were dissected and incubated in 0.005% collagenase IV 
(Sigma-Aldrich) at 37°C for 1h and in IMDM medium 
with 10% FCS for a further 2 hours at 37°C/5% CO2. Cell 
suspensions were assessed by flow cytometry for EGFP 
expression, after exclusion of dead cells by Live/Dead 
fixable Aqua kit (Life Technologies). An aliquot of the 
cells was kept for real-time qPCR analysis of SV40 Large 
T Antigen expression, to identify whether the lymph node 
was indeed metastatic. 
To evaluate EGFP+ cell infiltration within E.G7-
OVA tumors, tumor sections were incubated for 1h at 
RT with rabbit anti-EGFP (A10263, Invitrogen) and 
for 1h at RT with Streptavidin-peroxidase (Biocare 
Medical). Immunoreactivity was visualized with 
3,3-diaminobenzidine (DAB, Biocare Medical). All 
sections were counterstained with hematoxylin and 
photographed with an Olympus BX53 microscope with a 
digital camera. EGFP+ cells were determined with ImageJ 
software and expressed as number of positive cells divided 
by the total section area. 
For co-staining of T cells and tumor cells, 
the TRAMP SV40 TAg+ lymph node sections were 
incubated for 1h at RT with rabbit anti-EGFP (A10263, 
Invitrogen) and rabbit anti-SV40 T (sc-20800, Santa Cruz 
Biotechnology) and then for 15’ at RT with Streptavidin-
peroxidase (Biocare Medical). Endogenous peroxidase 
was blocked by incubation with Peroxidased I (Biocare 
Medical) for 20 min at RT and nonspecific sites were 
blocked with BSA (Euroclone) 1h RT. Immunoreactivity 
for anti-EGFP was visualized with DAB. After wash with 
TBS, the sections were incubated for 30’ with MACH 4 
Universal AP Polymer Kit. Endogenous phosphatase was 
blocked by incubation with Levamisole (Dako) for 5’RT. 
Immunoreactivity for anti-SV40 T was visualized with 
Ferangi Blue (Biocare Medical). 
Ex vivo 2-photon microscopy of lymph nodes
Lymph nodes were harvested and fixed in PFA 
4% overnight. Images were captured with a TrimScope 
II multiphoton microscope (LaVision) using a 20x/1.0 
Olympus LUMPLFL-WI objective. Excitation was 
provided by a Chameleon Ultra II Ti:Sa laser tuned at 
840nm for collagen second harmonic signal (SHG) or at 
920nm for EGFP excitation. Three-dimensional mosaic 
stacks of the first 20-50 μm were captured with 5-10% 
overlap and 2 μm z-step. Raw images were saved as OME 
TIFFs, then reconstructed with ImageJ/FIji Stitching 
Plugin [57]. Images are displayed as a maximum-intensity 
projection of 10-μm-z-stack. Collagen density analysis was 
conducted on ImageJ/Fiji. SHG channel was thresholded 
with fixed threshold levels, followed by image conversion 
to binary. For each slice, the capsule region was selected 
with hand drawing tool to exclude background and artifact 
regions. Drawing error was taken into account with a 2 
pixel error on the hand-drawn perimeter. White/black 
pixel density was measured on these regions. Cells in each 
lymph node were counted with Imaris software (Oxford 
Instruments) and Spot Detection module. To calculate 
background threshold, we measured average background 
autofluorescence in wild-type lymph nodes from untreated 
mice with ImageJ. Lymph node volume was calculated 
with Cavalieri Principle approximation, multiplying each 
area by the z-step.
Chemokine expression by Real-Time PCR
Tumor masses and prostates were harvested in 
RNA Later (Ambion) and homogenized with Tissue 
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Lyser II (QIAGEN). Total RNA was extracted with 
RNeasy Mini Kit (QIAGEN). Inguinal lymph nodes and 
paraortic lymph nodes were digested with Collagenase IV 
(Sigma-Aldrich) and total RNA was extracted from 1x105 
cells using RNeasy Micro Plus Kit (QIAGEN). After 
quantification, RNA was reverse-transcribed into cDNA 
using High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems). Within each experiment the same 
amount of cDNA was used, in the range 14-60 ng/reaction. 
Real-time qPCR was performed using TaqMan gene 
expression assays (CCL2 ID: Mm00441242_m1, CCL5 
ID: Mm01302427_m1, CXCL12 ID: Mm00445553_
m1, CXCL9 ID: Mm00434946_m1, CXCL10 ID: 
Mm00445235_m1, CXCL11 ID: Mm00444662_m1 and 
Rn18S ID: Mm03928990_g1). SV40 Large T antigen 
expression was assayed using a custom-made commercial 
TaqMan gene expression assay.
T cell-mediated cytotoxicity assay
Cell-mediated cytotoxicity was assayed as in [58], 
using CD8+ T cells from C57BL/6 spleens and inguinal 
lymph nodes, transduced with TCR OTI-2A.pMIG II/
m6p-egfp[Blast] and TCR OTI-2A.pMIG II /m5p-
CCR2-2A-egfp as effector cells and the E.G7 cell line as 
target cells. Target cells were labeled with CellTracker™ 
Orange CMTMR Dye (Life Technologies) and cell death 
was assessed by 7-aminoactinomycin D (7-AAD) (Life 
Technologies) on FACS (BD).
Costimulation and migration assay
CD8+ T cells were treated according to the 
preparative protocol for ACT, as described above. 
Following the resting period in IL-2/IL-7/IL-15, they were 
plated at 2 x 105 cells/well in flat 96-well plates and were 
either unstimulated or treated with CCL2 (100ng/mL) in 
fluid phase and/or pre-coated anti-CD3e and/or anti-CD28, 
using clones and concentrations as above. The cells were 
harvested for analysis after a further 18 hours and stained 
using anti-CD69 (H1.2F3; BD) and anti-CD25 (BPC61.5; 
eBiosciences). For the migration assay, Costar (Corning) 
24-well plates with 3 μm pore size were used. Transduced 
T cells were collected, counted and resuspended in IMDM 
BSA 0,1% at 3 x 106 cells/mL. 100 μL of cells were placed 
in the upper chamber. The bottom chamber was filled with 
500 μL of IMDM BSA 0,1% with or without CCL2 (100 
ng/mL). Cells were incubated at 37°C for 2 h to allow 
migration. Migrated cells were collected from the bottom 
chambers and counted using FACS (BD). 
In vivo tumor growth evaluation
C57BL/6 mice were injected on the right flank with 
5x105 E.G7-OVA cells. The tumors were allowed to grow 
for 24 days. Mice were treated in one of three groups: a) 
not treated b) treated with CD8+ T cells transduced with 
TCR OTI-2A.pMIG II and m6p-egfp[Blast] c) treated with 
CD8+ transduced with TCR OTI-2A.pMIG II and m5p-
CCR2-2A-egfp. The same number of TCR OTI-2A.pMIG 
II expressing T cells were injected for both groups. 7x105 
transduced CD8+ T cells per mouse were administered 
intravenously on day 8 and day 16 after tumor challenge. 
On day 16 the tumor masses were monitored by radiance 
emission of specific in vivo tumor marker IntegriSense 
750 (Perkin-Elmer) [59], injected the previous day. The 
radiance was measured by IVIS Lumina (Perkin-Elmer). 
On day 24 the tumor masses were monitored again 
immediately after sacrifice and harvesting. Grubb’s test 
was applied on the entire data set, identifying two spurious 
outliers. 
Assessment of collagen content in PANC02 tumors
C57BL/6 or RAG2-/- mice were injected 
subcutaneously on the right flank with 5x105 PANC02 
cells. The tumors were allowed to grow for 3 weeks. 
Harvested mouse tumors were fixed in 4% formalin, 
processed for paraffin embedding and sectioned at 3µm. 
Tissue collagen content was determined by staining 
sections in Masson trichrome (VWR International). 
Images of Masson’s trichrome staining were acquired with 
the Olympus VS120 dotSlide and analyzed to quantify 
the fibrotic areas, measured as collagen-stained area as 
a percentage of total section area, within each region of 
interest. The slides were additionally analyzed using SHG 
2-photon microscopy, as described above.
T cell density distribution analysis 
Tumors from C57BL/6 or RAG-/- mice that had 
received adoptively transferred Cell Tracker Orange 
CMTMR (Life Technologies)-labeled CD3+ cells were 
fixated in 4% PFA, processed for paraffin embedding and 
sectioned at 3µm. Samples were then either DAB stained 
for CD3 and acquired with an Olympus VS120 dotSlide 
slide scanner or acquired as is at 2-photon microscope 
for CMTMR fluorescence and SHG. Whole tumor slides 
were acquired and reconstructed with 20x magnification as 
previously described. Images were analyzed with a custom 
ImageJ plugin to generate a distribution of cells as a 
function of distance from tumor margin. Cells recognized 
by the algorithm were thresholded by signal intensity and 
with an upper size limit of 200 μm2. 
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For the analysis of the contribution of T cells versus 
B cells to peritumoral fibrosis, C57BL/6 mice were 
injected intra-peritoneally with 250 µg B cell-depleting 
mouse anti-mouse CD20 antibody (clone 5D2, Genentech 
Inc.) or vehicle (PBS). Alternatively, they were injected 
with 250 µg T cell-depleting armenian hamster anti-mouse 
CD3e (BioXCell, InVivo plus, clone 145-2C1) or isotype 
control (BioXCell, InVivo Plus Armenian Hamster IgG). 
4 days later (“day 0”), they received 7.5x105 PANC02 
cells per mouse subcutaneously. T cell and B cell levels 
were monitored via FACS for CD19 (1D3, eBioscience), 
CD4 (RM4-5, BD) and CD8 (53-6.7, BD) on day -5, -1, 
16 and 21. On day 21, harvested tumors were analyzed by 
staining sections with Masson’s trichrome, as above.
Statistical analysis
Statistical analysis was performed with GraphPad 
Prism software, using unpaired t-test/1-way ANOVA for 
Gaussian or Mann Whitney/non-parametric ANOVA tests 
for non-Gaussian distributions, after normality testing. 
Grubb’s test was applied to identify spurious outliers.
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